(Total Views: 337)
Posted On: 04/03/2017 11:38:17 PM
Post# of 102854
RXMD is SOLID.
It's PROFITABLE
GROWING,
HAS LOWERED THE O/S FROM 352M LAST YEAR TO 345M THIS YEAR
$18M in SALES IN '16 WITH $22M TARGET FOR '17
CEO IN INVESTORS CONFERENCE CALL TODAY SAID NO DILUTION FOR THE NEAR FUTURE.
COMPANY CASH ON HAND IS $800K+
SHARE PRICE JUST BOUNCED HARD OFF 52 WEEK LOWS
This IS A BUY AND HOLD LONG.
It's PROFITABLE
GROWING,
HAS LOWERED THE O/S FROM 352M LAST YEAR TO 345M THIS YEAR
$18M in SALES IN '16 WITH $22M TARGET FOR '17
CEO IN INVESTORS CONFERENCE CALL TODAY SAID NO DILUTION FOR THE NEAR FUTURE.
COMPANY CASH ON HAND IS $800K+
SHARE PRICE JUST BOUNCED HARD OFF 52 WEEK LOWS
This IS A BUY AND HOLD LONG.
(0)
(0)
